Treatment options for HER2-expressing colorectal cancer: updates and recent approvals.

Authors:
Zheng-Lin B; Bekaii-Saab TS.

Journal:
Ther Adv Med Oncol

Publication Year: 2024

DOI:
10.1177/17588359231225037

PMCID:
PMC10798128

PMID:
38249334

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Adv Med Oncol

Abbreviation: Ther Adv Med Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-an…
Petrelli F; Antista M; Marra F and 8 more (2024) - Transparency Score: 3/6
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluati…
Sepe P; Procopio G; Pircher CC and 16 more (2024) - Transparency Score: 4/6
A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line …
Yu N; Huang S; Zhang Z and 9 more (2024) - Transparency Score: 4/6
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X and 3 more (2024) - Transparency Score: 3/6
Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ogata T; Narita Y; Oze I and 14 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Tanios Bekaii-Saab: Boehringer Ingelheim, TreosBio, Sobi (C/A), Ipsen, Array Biopharma, Seattle Genetics, Bayer, Genentech, Incyte, Merck (C/A [institutional]), Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Array Biopharma, Genentech, Abgenomics, Incyte, BMS (RF [institutional]), IDMC/DSMB (to self): Astra Zeneca, Exelixis, Lilly, PanCan, 1Globe (IDMC/DSMB); Imugene, Immuneering, Sun Biopharma (SAB), Inventions/Patents: WO/2018/183488 and WO/2019/055687 (IP)."

Evidence found in paper:

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025